PATEL DINESH V PH D 4

What Happened
Dinesh V. Patel, Ph.D., President, CEO and Director of Protagonist Therapeutics (PTGX), sold 34,438 shares on 2026-01-20 at $82.48 per share, generating gross proceeds of $2,840,446. The Form 4 lists the transaction as an open-market/private sale and includes a footnote that the sale was to cover tax withholding obligations incurred upon settlement of restricted stock units (RSUs). Sales made to satisfy tax withholding are commonly routine and do not necessarily signal a change in insider sentiment.

Key Details

• Transaction date: 2026-01-20; Form 4 filed 2026-01-21 (appears timely).
• Price: $82.48 per share; shares sold: 34,438; proceeds: $2,840,446.
• Reported as: Sale (S) — open market or private sale.
• Footnote: Sale to cover tax withholding on RSU settlement.
• Shares owned after transaction: not specified in the provided filing excerpt.

Context
This was a tax-withholding sale tied to RSU vesting rather than a discretionary open-market sell driven by investment views. For retail investors, note that purchases by insiders often carry more weight as signals of confidence; routine, tax-related disposals are common and typically less informative about management’s outlook.